First Eagle Investment Management’s Alexion Pharmaceuticals ALXN Stock Holding History

First Eagle Investment Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-50,000	Closed	-$4.49M	–	113
2020 Q1	$4.49M	Buy	+50,000	New	+$4.91M	0.02%	101
2019 Q2	–	Sell	-145,900	Closed	-$19.7M	–	162
2019 Q1	$19.7M	Hold	145,900	–	–	0.05%	103
2018 Q4	$14.2M	Sell	145,900 -124,682	-46%	-$14.7M	0.04%	111
2018 Q3	$37.6M	Buy	270,582 +55,600	+26%	+$6.97M	0.09%	95
2018 Q2	$26.7M	Buy	+214,982	New	+$25.1M	0.07%	108

Other funds holding ALXN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

First Eagle Investment Management's ALXN Position: Q2 2020 in Review

First Eagle Investment Management sold out of Alexion Pharmaceuticals (ALXN) in Q2 2020, closing a stake of 50,000 shares — an estimated $4.49M sold.

First Eagle Investment Management first reported a position in ALXN in Q2 2018 and held it in 5 quarters. The position peaked at $37.6M in Q3 2018. 707 funds tracked by Wall St. Rank hold ALXN as of Q2 2020.

First Eagle Investment Management reported no remaining Alexion Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
First Eagle Investment Management sold 50,000 Alexion Pharmaceuticals shares in Q2 2020, an estimated $4.49M.
First Eagle Investment Management first reported a position in Alexion Pharmaceuticals in Q2 2018 and held it in 5 quarters.
First Eagle Investment Management's Alexion Pharmaceuticals position peaked at $37.6M in Q3 2018.
707 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2020.

Based on First Eagle Investment Management's 13F filing for Q2 2020, filed 10 Aug 2020.